| Objective: Beta-blockers have gradually become an attractive option for the treatment of infantile hemangiomas(IHs).Topical application of beta-blockers is preferred over oral administration since their potential systemic adverse effects.Besides timolol,as the mainstream medication for superficial IH,however other types of beta-blockers are rarely reported.To develop a new effective approach,in this present study,betaxolol as a topical treatment for IHs was specifically observed and recorded.Methods: Seventy-four infants with superficial hemangiomas admitted to the First Affiliated Hospital of Xinjiang Medical University from January 2018 to May 2019 were all treated by topical application of betaxolol.The changeable indicators such as color,size,tension and thickness were monthly recorded and evaluated according to visual analog scales.Multi-factor analysis of variance(MANOVA)with repeated measurements and Kruskal-Wallis H nonparametric test were performed to compare the clinical effectiveness across different groups.Results:After six months of treatment,33.78%(25/74)got excellent results,55.41%(41/74)had good response,8.11%(6/74)had moderate response and 2.70%(2/74)had poor response respectively.During the whole procedure,neither local discomfort nor systemic complications had been found.There was no significant difference in gender and location of occurrence among groups(P>0.05),while the effect of topical application of betaxolol was optimum in the children aged 0-3 months(P=0.002).None of three age groups had statistically significant discrepancy of heart rate and blood pressure after accepting treatment(one month,P=0.618;four months,P=0.138;six months,P=0.757).Conclusions: Our study showed that topical administration of betaxolol was effective and well-tolerated for superficial IHs particularly in the early proliferative stage.However,its3 safety and efficacy need continuous studies to be confirmed. |
PDF Full Text Request